Back to News
Market Impact: 0.15
AbbVie To Present Positive Phase 3 Etentamig Data At IMS 2026
Source: Nasdaq
Healthcare & Biotech
AbbVie will present full Phase 3 results for etentamig, an investigational CMA x CD3 bispecific T-cell engager, at the International Myeloma Society Annual Meeting in Glasgow on September 23-26, 2026. The announcement signals an upcoming clinical-data catalyst, but provides no efficacy, safety, or regulatory results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
ABBV0.30
More News
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- Wells Fargo raises Regeneron stock price target to $925 on execution
- Deutsche Bank downgrades Novartis stock rating to sell on valuation